American Society of Clinical Oncology Archives

CTCA recruits patients for groundbreaking clinical trial

VisionGate

Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) will be the first hospital in Arizona to work on a groundbreaking targeted drug trial for cancer treatment. The study launched earlier this year and will evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about additional uses of… Read More →

NCI funds TGen-led cancer study training

brain cancer

The National Cancer Institute (NCI) awarded a 5-year, $1.125 million grant to continue an innovative and unique oncology training program for newly minted physicians developed and overseen by Dr. Daniel Von Hoff, distinguished professor and physician-in-chief at the Translational Genomics Research Institute (TGen). Convened by the American Association for Cancer Research (AACR) and the American Society… Read More →

CTCA hosts its first cancer treatments conference

VisionGate

Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western) is hosting its first ever Annual New Treatments in Oncology (ANTO) conference, focused on advances in cancer research, new treatments and patient care. The two-day ANTO event will take place on May 1-2 at the W Scottsdale hotel. “We believe we have a… Read More →

SHC’s Von Hoff honored for cancer advances

In association with its 50th anniversary, the American Society of Clinical Oncology (ASCO) has named Daniel D. Von Hoff, M.D., FACP, one of ASCO’s 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care. Dr. Von Hoff is Chief Scientific Officer for Scottsdale Healthcare’s Virginia G. Piper Cancer Center… Read More →

TGen-TD2-Scottsdale Healthcare study benefits patients

The Side-Out Foundation’s breast cancer pilot study, led by the Translational Genomics Research Institute (TGen), Translational Drug Development (TD2) and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling. Specifically, 52 percent of patients with advanced breast cancer received clinical benefit – meaning their disease was controlled… Read More →

TGen, Scottsdale Healthcare study may help pancreatic cancer patients

clinical research advantage - vaccines
by in Business News | Healthcare

A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard treatment. The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study was led by physicians from Scottsdale Healthcare’s Virginia G. Piper Cancer Center Clinical Trials, a partnership… Read More →